ReviewGalen medical journal2026
Lifestyle Modification and Bariatric Surgery in Type 2 Diabetes Remission : Short title: Diabetes Remission Strategies in T2DM.
Review in Galen medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) has traditionally been regarded as a chronic and progressively worsening disease. This paradigm is now challenged by evidence showing that remission is achievable in selected patients, particularly when interventions produce substantial and sustained weight loss. This narrative review synthesizes current evidence on lifestyle modification and bariatric/metabolic surgery as remission-inducing strategies, with emphasis on mechanisms, comparative efficacy, predictors of response, and limitations. Intensive lifestyle interventions, especially very-low-calorie diets and total diet replacement programs, can induce normoglycemia in selected individuals through reductions in hepatic and pancreatic fat, improved insulin sensitivity, and partial recovery of β-cell function. However, durability is limited and depends strongly on sustained weight loss. Bariatric/metabolic surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, achieves higher and more durable remission rates than non-surgical approaches. These effects are mediated by both weight loss and weight-independent mechanisms, including enhanced incretin signaling, altered bile acid metabolism, and gut microbiota changes. Consistent predictors of remission include shorter diabetes duration, lower baseline HbA1c, reduced treatment burden, greater weight loss, and preserved β-cell function. Despite these advances, relapse remains common, long-term randomized data are limited, and important barriers persist, including procedural risk, cost, and inequitable access. Overall, the evidence supports a shift from a model of inevitable progression toward one of potentially reversible metabolic dysfunction, with important implications for early, remission-oriented care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.